Treatment of Nonmetastatic Castration Resistant Prostate Cancer

被引：1
|
作者：
Luo, Jia [1 ]
Beer, Tomasz M. [2 ]
Graff, Julie N. [2 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] VA Portland Hlth Care Syst, Portland, OR USA
来源：
ONCOLOGY-NEW YORK | 2016年 / 30卷 / 04期
关键词：
METASTASIS-FREE SURVIVAL; ANDROGEN-RECEPTOR GENE; ANTIANDROGEN WITHDRAWAL; PHASE-III; MEN; THERAPY; HORMONE; ENZALUTAMIDE; BICALUTAMIDE; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.
引用
收藏
页码：336 / 344
页数：9
相关论文
共 50 条
  • [1] Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
    Yildizhan, Mehmet
    Gemalmaz, Hakan
    Ertek, Mehmet Sirin
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (02): : 120 - 127
  • [2] Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
    Altavilla, Amelia
    Casadei, Chiara
    Lolli, Cristian
    Menna, Cecilia
    Ravaglia, Giorgia
    Gurioli, Giorgia
    Farolfi, Alberto
    Brighi, Nicole
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Schepisi, Giuseppe
    Rossi, Lorena
    Gargiulo, Stefania
    Lisotti, Ivana
    De Giorgi, Ugo
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2091 - 2099
  • [3] Nonmetastatic Castration-Resistant Prostate Cancer
    Hong, Jun Hyuk
    Kim, Isaac Y.
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (03) : 153 - 160
  • [4] Recent Updates in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
    Berger, Aaron
    ONCOLOGY-NEW YORK, 2021, 35 (12): : 846 - 848
  • [5] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1235 - 1246
  • [6] Management of nonmetastatic castration-resistant prostate cancer
    Traboulsi, Samer L.
    Saad, Fred
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 366 - 371
  • [7] Managing Nonmetastatic Castration-resistant Prostate Cancer
    Mateo, Joaquin
    Fizazi, Karim
    Gillessen, Silke
    Heidenreich, Axel
    Perez-Lopez, Raquel
    Oyen, Wim J. G.
    Shore, Neal
    Smith, Matthew
    Sweeney, Christopher
    Tombal, Bertrand
    Tomlins, Scott A.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2019, 75 (02) : 285 - 293
  • [8] FDA APPROVES FIRST TREATMENT FOR NONMETASTATIC, CASTRATION-RESISTANT PROSTATE CANCER
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2018, 118 (06) : 26 - 26
  • [9] Physician preferences for nonmetastatic castration-resistant prostate cancer treatment in China
    Fan, Yu
    Guo, Xuanjun
    Campobasso, Davide
    He, Zhisong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] Influence of modern diagnosticmethods on the treatment of nonmetastatic castration-resistant prostate cancer
    Kretschmer, A.
    Tilki, D.
    UROLOGE, 2019, 58 (05): : 529 - 534
12345